MEDTRONIC VASCULAR GALWAY UNLIMITED COMPANY
Location
Founded
1989-12-19
Website
Risk Signals
4960 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Surgical and Medical Instruments and Apparatus, Drugs, Drug Proprietaries, and Druggists' Sundries), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about MEDTRONIC VASCULAR GALWAY UNLIMITED COMPANY
Live alerts from global media, monitored by Business Radar
2025-01-22 (marketbeat.com)
Medtronic (NYSE:MDT) Shares Down 0.1% - Time to Sell?
Medtronic (NYSE:MDT) Stock Price Down 0.1% - Here's What Happened
Read more
2024-12-17 (marketbeat.com)
Medtronic (NYSE:MDT) Trading 0.6% Higher - What's Next?
Medtronic (NYSE:MDT) Shares Up 0.6% - Here's What Happened
Read more
2024-12-09 (marketbeat.com)
Medtronic (NYSE:MDT) Stock Price Up 0.3% - Should You Buy?
Medtronic (NYSE:MDT) Trading Up 0.3% - Here's What Happened
Read more
2024-12-05 (marketbeat.com)
Stifel Financial Corp Raises Holdings in Medtronic plc (NYSE:MDT)
Stifel Financial Corp grew its position in shares of Medtronic plc (NYSE:MDT - Free Report) by 2.9% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 5,842,020 shares of the medical technology company's stock after purchasing an additional 1
Read more
2024-11-23 (finmarket.ru)
Finam maintains Medtronic stock rating at "buy" level
Finam maintains a “buy” rating for Medtronic PLC shares with a target price of $101.8 per share, according to Zarina Saidova, a leading analyst at the stock analysis department.
Read more
2024-11-20 (marketbeat.com)
Medtronic (NYSE:MDT) Price Target Lowered to $98.00 at Wells Fargo & Company
Wells Fargo & Company lowered their price objective on shares of Medtronic from $106.00 to $98.00 and set an "overweight" rating for the company in a research note on Wednesday.
Read more
2024-10-10 (marketbeat.com)
Medtronic (NYSE:MDT) Upgraded by Royal Bank of Canada to Outperform
Royal Bank of Canada upgraded shares of Medtronic from a "sector perform" rating to an "outperform" rating and boosted their target price for the company from $98.00 to $105.00 in a report on Thursday.
Read more
2024-09-05 (finmarket.ru)
Finam maintains Medtronic stock rating at "buy" level
Finam maintains a buy rating on Medtronic PLC shares with a target price of $101.8 per share, which corresponds to a growth potential of 14.4%, according to Zarina Saidova, a leading analyst at the stock research department.
Read more
2023-04-14 (defenseworld.net)
Medtronic plc (NYSE:MDT) Given Average Rating of “Hold” by Analysts
Shares of Medtronic plc (NYSE:MDT – Get Rating) have been assigned a consensus rating of “Hold” from the twenty-two research firms that are currently covering the company, Marketbeat.com reports.
Read more
2017-11-08 (massdevice.com)
FDA puts Second Sight Medical's next-gen Orion 'bionic eye' on the fast track
Second Sight Medical (NSDQ:EYES) said today that the FDA put its Orion “bionic eye” on the fast track to approval. The Orion device is a cortical visual prosthesis that uses a camera and a brain implant to bypass the optic nerve in visually impaired patients.
Read more